1 Biotech Stock Set to Rebound in 2026

The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate.For all the enthusiasm around GLP-1s, also known as weight-loss drugs, Novo Nordisk (NVO 1.70%) tumbled nearly 42% in 2025. The once hot stock was confounded by headwinds, including rivals making progress in the weight-loss arena and the emergence of cheaper generics.Fast-forward to 2026, and the stock is already shedding last year's bear market conditions. Shares of the maker of Wegovy are up 25% year to d ...